Rare pathogenic variants in G-protein coupled receptor genes involved in gut-to-host communication are associated with cardiovascular disease risk

Short title: Gut-to-host receptors and cardiovascular disease risk

Leticia Camargo Tavares[1*]; Rikeish R. Muralitharan[1]; Matthew Snelson[1]; Francine Z. Marques[1,2*]

[1]Hypertension Research Laboratory, Victorian Heart Institute and Department of Pharmacology, Biomedical Discovery Institute, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia; [2]Heart Failure Research Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia.

*Corresponding authors: Dr Leticia Camargo Tavares, PhD, Postdoctoral Research Fellow, Hypertension Research Laboratory, School of Biological Sciences, Faculty of Science, Monash University, Melbourne, Australia. Email: leticia.camargotavares1@monash.edu; Prof Francine Marques, Hypertension Research Laboratory, Victorian Heart Institute, Level 2, Victorian Heart Hospital, 631 Blackburn Road Clayton, VIC 3168 Monash University, Melbourne, Australia, Phone: +61-03-9905 6958. E-mail: francine.marques@monash.edu

Funding Information: F.Z.M. is supported by a Senior Medical Research Fellowship from the Sylvia and Charles Viertel Charitable Foundation, a National Heart Foundation Future Leader

Fellowship (105663), and National Health & Medical Research Council (NHMRC) Emerging Leader Fellowship (GNT2017382). M.S. is supported by a National Heart Foundation Postdoctoral Fellowship (106698).

Conflict of interest

None.

Data availability

This research has been conducted using the UK Biobank Resource under Application Number 86879. This work uses data provided by patients and collected by the NHS as part of their care and support. Full methods can be accessed at medRxiv:

https://doi.org/10.1101/2024.10.01.24314734.

Acknowledgement

We would like to acknowledge Monash Bioinformatics Platform for access to the M3 servers, as well as the participants of the UK Biobank. This research has been conducted using the UK Biobank Resource under Application Number 86879.

Author contributions

LCT led and FZM supported study design and conception; LCT led the formal data analysis and visualization; LCT led and RRM, MS, and FZM supported data interpretation; LCT led and RRM, MS, and FZM supported drafting the manuscript; all authors approved the final version of the manuscript.

Keywords: Genomics; Rare variants; G-protein couple receptors; Short-chain fatty acids; Hypertension; Major adverse cardiac events.

Gut microbial metabolites called short-chain fatty acids (SCFAs) confer protection against

cardiovascular disease (CVD) and its primary risk factor, hypertension.[1] Dietary fibers reach the

large intestine undigested, where some are metabolized by fermentative microbes, releasing

SCFAs as by-products. These metabolites lower blood pressure in humans and protect against

cardiac hypertrophy and fibrosis in mice.[1, 2] Proposed mechanisms include anti-inflammatory

signaling activated by the binding of SCFAs to G-protein-coupled receptors (GPCRs,

particularly *FFAR3*/GPR41, *FFAR2*/GPR43, and *HCAR2*/GPR109A), as suggested by previous

mouse studies using knockout strains.[1, 3] Here, we conducted a large-scale population-based

study aimed at determining if rare pathogenic variants (RPVs) affecting SCFA-sensing GPCR

genes increase the risk in humans of hypertension and major adverse cardiac events (MACE),

including acute coronary syndrome, heart failure, and ischemic stroke.

We used the population healthcare, lifestyle, and whole-exome sequencing (WES) data

from the UK Biobank, available for 393,649 participants of white-European genetic ancestry

(**Figure A**). UK Biobank has approval from the Northwest Multi-Centre Research Ethics

Committee and conforms to the Declaration of Helsinki principles. Informed written consent was

given before the inclusion of subjects in the study. Rare (minor allele frequency <1%) variants in

the GPCR genes *FFAR3*, *FFAR2* and *HCAR2* and their genotypes were extracted from quality-

controlled WES data, based on genomic coordinates. We identified a subset of 158 RPVs with

predicted high-impact functional consequences or missense-pathogenic likelihood scores (**Figure**

A). Annotations were based on the Ensembl Variant Effect Predictor tool

(http://www.ensembl.org/info/docs/tools/vep), as performed previously.[4] Cases and controls for

hypertension and MACE subtypes were identified based on diagnoses from hospital admissions

(recorded as ICD-10 – International Classification of Disease 10th version - codes), self-reported

medical histories from health-related questionnaires, surgical records and death registries

(**Figure A**). The characteristics of the study cohort are detailed in **Figure B**.

Multiple and single GPCR gene-based collapsing analyses were conducted to test

whether there is a significant difference in the counts of individuals carrying at least one rare-

pathogenic variant that disrupts gene function (carriers) between cases versus controls , using

multivariable-adjusted regression models.[5] Age- and sex-adjusted models, either excluding or

including BMI as a covariate (*model 1* and *model 2*, respectively), revealed the prevalence of

RPV carriers affecting any GPCR gene of interest was significantly higher in participants with

hypertension and MACE compared to controls (**Figure C**). Given the occurrence of MACE is

recognized to be associated with standard modifiable cardiovascular risk factors (SMuRFs) –

including hypertension, diabetes, hypercholesterolemia, and smoking – we further adjusted

MACE analyses for these additional covariates (*model 3*). SMuRFs-adjusted analyses confirmed

a significantly increased risk of MACE among GPCR RPV carriers, independent of these

additional risk factors (**Figure C**). Finally, when GPCR genes were tested individually, carrying

RPVs in the *HCAR2* (GPR109A) gene was associated with a markedly increased risk of heart

failure, while carrying RPVs in the *FFAR2* (GPR43) gene was associated with an increased risk

of hypertension, with associations remaining significant after correction for multiple

comparisons (accounting for 3 GPCR genes and distinct models) (**Figure C**).

Next, to identify other diseases and conditions that are more common among

hypertension and MACE patients carrying GPCR RPVs (compared to non-carriers) and could

contribute to this association, we performed a comorbidity analysis by retrieving hospital

inpatient records for 1,259 ICD-10 codes (Chapters I–XIV) across 39,563,559 data-points (243

data-fields covering 162,813 cases for hypertension/MACE). After filtering for ICD-10 diseases

with a prevalence greater than 1% and adjusting for multiple comparisons (297 ICD-10 diseases

and two models), we found cardiomyopathy (ICD-10: I42) was more than twice as common in

hypertensive patients carrying GPCR RPVs (**Figure D**). Consistently, cardiac hypertrophy and

fibrosis have been observed in experimental mouse models that lack SCFA-sensing GPCR

genes.[1, 3]

Since SCFAs are produced primarily by the gut microbiota as a response to dietary fiber

intake, to further understand the complex relationship between fiber, gut-to-host communication,

and cardiovascular health, we investigated whether carrying GPCR RPVs increases the risk of

hypertension and MACE among individuals consuming an adequate-fiber diet. This would

support the hypothesis that fiber's beneficial cardiovascular effects depend upon GPCR

signaling. To estimate daily fiber intake, we studied a subset of UK Biobank participants with

dietary data, assessed by a 24-hour dietary recall of food intake on the previous day in five

different instances (n=168,142 with dietary data available for at least one instance). Based on

nutritional recommendations,[6] an adequate-fiber diet was defined as an average intake of ≥25

g/day for women and ≥30 g/day for men, leaving 13,858 participants for subsequent analyses.

Consistent with our hypothesis, the prevalence of hypertension was significantly higher among

GPCR RPVs carriers (**Figure E**), suggesting the cardiovascular benefits of fiber intake are

diminished in the presence of genetic impairments in SCFA-related GPCR signaling. No

significant associations were observed for MACE, likely due to the smaller sample size.

Furthermore, in the inadequate-fiber consumers subgroup (n=154,284), hypertension prevalence

was still higher in carriers versus non-carriers of RPVs (38.0% versus 34.9%), but it was no

longer significant (p>0.05). In the absence of sufficient fiber, SCFA production is minimal and,

thus, the benefit from SCFA signaling is likely blunted for both GPCR RPVs carriers and non-

carriers.

Overall, our findings elucidate gene-by-environment interactions and show that lack of

signaling via SCFA-sensing GPCRs, even when fiber intake is adequate, is associated with

human hypertension and MACE in a large population-based cohort from the UK. This

underscores the potential of targeting gut-to-host mechanisms through SCFA-sensing GPCRs as

a therapeutic strategy for hypertension and CVD.

References

1. Kaye DM, Shihata WA, Jama HA, Tsyganov K, Ziemann M, Kiriazis H, Horlock D,

Vijay A, Giam B, Vinh A, Johnson C, Fiedler A, Donner D, Snelson M, Coughlan MT,

Phillips S, Du XJ, El-Osta A, Drummond G, Lambert GW, Spector TD, Valdes AM,

Mackay CR, Marques FZ. Deficiency of Prebiotic Fiber and Insufficient Signaling

Through Gut Metabolite-Sensing Receptors Leads to Cardiovascular Disease. *Circulation*

2020;**141**:1393-1403.

2. Jama HA, Rhys-Jones D, Nakai M, Yao CK, Climie RE, Sata Y, Anderson D, Creek DJ,

Head GA, Kaye DM, Mackay CR, Muir J, Marques FZ. Prebiotic intervention with

HAMSAB in untreated essential hypertensive patients assessed in a phase II randomized

trial. *Nature Cardiovascular Research* 2023;**2**:35-43.

3. R Muralitharan R, Zheng T, Dinakis E, Xie L, Barbaro-Wahl A, Jama HA, Nakai M,

Patterson M, Leung KC, McArdle Z, Mirabito Colafella K, Johnson C, Qin W, Salimova

E, Bitto N, Liaskos MK, Kaye DM, O'Donnell JA, Mackay CR, Marques FZ. Gut

Microbiota Metabolites Sensed by Host GPR41/43 Protect Against Hypertension.

Circulation Research 2025.

4. Zheng T, Camargo-Tavares L, Bonfiglio F, Marques FZ, Naim HY, D'Amato M. Rare

Hypomorphic Sucrase Isomaltase Variants in Relation to Irritable Bowel Syndrome Risk

in UK Biobank. *Gastroenterology* 2021;**161**:1712-1714.

5. Povysil G, Petrovski S, Hostyk J, Aggarwal V, Allen AS, Goldstein DB. Rare-variant

collapsing analyses for complex traits: guidelines and applications. *Nature Reviews*

Genetics 2019;**20**:747-759.

6.   Jama HA, Snelson M, Schutte AE, Muir J, Marques FZ. Recommendations for the Use of

Dietary Fiber to Improve Blood Pressure Control. *Hypertension* 2024;**81**:1450-1459.

Figure legend

Figure. Rare pathogenic variants (RPVs) in short-chain fatty acid (SCFA)-sensing G-protein coupled receptors (GPCR) genes are associated with poor cardiovascular outcomes.

(A) Study design flowchart, including phenotype and RPVs definitions. RPVs were identified based on two classifications: (1) *'high-impact functional consequence'*, comprising stop gained/lost, frameshift, and splicing alterations based on Ensembl Variant Effect Predictor annotations; (2) *'pathogenic missense variants'*, comprising missense variants with pathogenic likelihood scores >0.564 from AlphaMissense, >0.025 from Mendelian Clinically Applicable Pathogenicity, or >20 from Combined Annotation Dependent Depletion. **(B)** Study cohort demographic and clinical characteristics, stratified as cases and controls for each phenotype of interest, encompassing hypertension (HTN), major adverse cardiac events (MACE) and MACE subtypes (acute coronary syndrome (ACS), heart failure (HF), and ischemic stroke). **(C)** Significant associations between GPCR RPVs and phenotypes' risk. **(D)** Increased cardiomyopathy prevalence in hypertensive cases carrying GPCR RPVs. **(E)** Increased hypertension prevalence in GPCR RPV carriers among adequate-fiber diet consumers.

Statistics: Multiple comparisons were corrected by false discovery rate using the Benjamini-Hochberg method (threshold q<0.05). **Panels C-E:** Odds-ratio (OR) and P values are derived from multivariable logistic regression analyses, adjusted for: age and sex (*model 1*); age, sex, and BMI (*model 2*); age, sex, BMI, and standard modifiable cardiovascular risk factors (SMurFs), including smoking (current/past), hypertension, diabetes, and hypercholesterolemia (*model 3*; only applied for MACE and subtypes). Genetic ancestry (10-top genetic principal components) was also included as covariate when testing the association between GPCR RPVs and phenotypes' risk (Panel C). All OR forest plots are in a $\log_{10}$ scale.

A

biobank uk

Individual quality control
- Withdrawn consent
- Sex mismatches (genetic vs reported)
- Genetic non-European
- Excess relatives (>10 with kinship≥0.0442)

Whole-exome sequencing
- Genotype call >95%
- Minor allele frequency <1%
- SCFA-sensing GPCR genes:
  - *FFAR3* (GPR41)
  - *FFAR2* (GPR43)
  - *HCAR2* (GPR109A)

N=393,649

Phenotypes

	controls	cases
HTN	241,884	151,765 (● ▲)
ACS	364,982	28,667 (● ▲ ◆ ■)
Stroke	381,280	12,369 (● ▲ ■)
HF	379,597	14,052 (● ▲ ■)
MACE	348,138	45,511 (● ▲ ◆ ■)

Legend: controls (blue), cases (orange)

Definition: ● Hospital records; ▲ Self-report; ◆ Surgical history; ■ Death register

Rare pathogenic variants (RPVs)

	High-impact functional consequence	Pathogenic missense
FFAR3	6 (24%)	19 (76%)
FFAR2	14 (20%)	57 (80%)
HCAR2	10 (16%)	52 (84%)
Any GPCR	30 (19%)	128 (81%)

B

	HTN controls	HTN cases	ACS controls	ACS cases	Stroke controls	Stroke cases	HF controls	HF cases	MACE controls	MACE cases
Demographical and clinical data										
Women (n, %)	141,134 (58.3)	71,584 (47.2)	205,130 (56.2)	7,588 (26.5)	207,841 (54.5)	48,77 (39.4)	207,803 (54.7)	4,915 (35.0)	197,861 (56.8)	14,857 (32.6)
Age, years (mean, SD)	55.07 (8.06)	59.85 (6.96)	56.58 (8.02)	61.18 (6.43)	56.77 (8.00)	61.48 (6.50)	56.72 (8.00)	62.30 (6.00)	56.34 (8.01)	61.30 (6.45)
Body mass index (BMI), kg/m^2 (mean, SD)	26.39 (4.21)	29.05 (5.08)	27.30 (4.72)	28.90 (4.75)	27.38 (4.73)	28.61 (5.00)	27.33 (4.68)	29.82 (5.74)	27.22 (4.67)	28.92 (5.03)
Systolic blood pressure, mmHg (mean, SD)	134.33 (17.36)	149.48 (19.42)	139.90 (19.54)	144.10 (20.23)	140.04 (19.56)	145.19 (20.73)	140.02 (19.53)	145.14 (21.37)	139.63 (19.45)	144.60 (20.40)
Diastolic blood pressure, mmHg (mean, SD)	79.83 (9.76)	86.09 (10.85)	82.29 (10.60)	81.80 (11.19)	82.22 (10.60)	83.18 (11.26)	82.26 (10.60)	82.07 (11.66)	82.23 (10.57)	82.40 (11.22)
Smoking (current or past) (n, %)	69,997 (28.9)	58,082 (38.3)	113,954 (31.2)	14,125 (49.3)	122,407 (32.1)	5,672 (45.9)	121,062 (31.9)	7,017 (49.9)	106,536 (30.6)	21,543 (47.3)
Hypertension (n, %)	0 (0.0)	151,765 (100.0)	129,456 (35.5)	22,309 (77.8)	142,578 (37.4)	9,197 (74.3)	140,422 (37.0)	11,343 (80.7)	117,302 (33.7)	34,463 (75.7)
Diabetes (n, %)	7,622 (3.2)	26,994 (17.8)	27,695 (7.6)	6,921 (24.1)	31,806 (8.3)	2,810 (22.7)	30,330 (8.0)	4,286 (30.5)	24,115 (6.9)	10,501 (23.1)
Hypercholesterolemia (n, %)	20,875 (8.6)	59,971 (39.5)	60,536 (16.6)	20,316 (70.9)	74,002 (19.4)	6,844 (55.3)	72,775 (19.2)	8,071 (57.4)	52,896 (15.2)	27,950 (61.4)
Any SMuRF (n, %)	85,398 (35.3)	151,765 (100.0)	210,340 (57.6)	26,823 (93.6)	226,078 (59.3)	11,085 (89.6)	224,160 (59.1)	13,003 (92.5)	195,517 (56.2)	41,646 (91.5)
GPCR RPVs carriers										
Any GPCR (GPR 41/43/109A) (n, %)	1167 (0.48)	836 (0.55)	1833 (0.50)	170 (0.59)	1932 (0.51)	71 (0.57)	1914 (0.50)	89 (0.63)	1725 (0.50)	278 (0.61)
FFAR3 (GPR41) (n, %)	490 (0.20)	319 (0.21)	747 (0.20)	62 (0.22)	782 (0.21)	27 (0.22)	775 (0.20)	34 (0.24)	703 (0.20)	106 (0.23)
FFAR2 (GPR43) (n, %)	413 (0.17)	315 (0.21)	662 (0.18)	66 (0.23)	700 (0.18)	28 (0.23)	701 (0.18)	27 (0.19)	626 (0.18)	102 (0.22)
HCAR2 (GPR109A) (n, %)	269 (0.11)	204 (0.13)	431 (0.12)	42 (0.15)	457 (0.12)	16 (0.13)	445 (0.12)	28 (0.20)	403 (0.12)	70 (0.15)

Quantitative variables are shown as 'mean (SD)' and qualitative as 'n (%)'

Multi-gene — Any GPCR

RPVs prevalence (%) — OR (95% CI) — P — q

HTN
	RPVs prevalence (%)	P	q
model 1	controls 0.48%	0.015	0.015
model 2	cases 0.55%	0.015	0.015
		0.014	0.015

Single-gene

FFAR2 (GPR43) — HTN
	RPVs prevalence (%)	P	q
model 1	controls 0.17%	0.011	0.033
model 2	cases 0.21%	0.005	0.033

Any GPCR — MACE
	RPVs prevalence (%)	P	q
model 1	controls 0.5%	0.005	0.009
model 2		0.006	0.009
model 3	cases 0.61%	0.009	0.009

HCAR2 (GPR109A) — HTN
		P	q
	controls 0.12%	0.007	0.034
		0.007	0.034
	cases 0.2%	0.012	0.036

FFAR2 (GPR43):
	prevalence	P	q
	0.17%	0.011	0.033
	0.17%	0.011	0.033
	0.21%	0.005	0.033

HCAR2 (GPR109A):
	prevalence	P	q
controls	32.5%	2.5e−03	0.005
cases	48.6%	5.2e−03	0.005
controls	1.2%	9.3e−05	0.028
cases	2.8%	7.8e−05	0.028

	prevalence	P	q
controls	0.12%	0.007	0.034
		0.007	0.034
cases	0.2%	0.012	0.036